| 8:00–9:00 |
Registration and Continental Breakfast
|
| 9:00–9:15 |
Welcome Remarks
Speakers:
- Carola Schropp – President, EBD Group
- Yuwen Liu, MBA – Chairwoman and CEO, BioBay
- Greg B. Scott – CEO, ChinaBio LLC
- Barry Yang – Chairman, Suzhou SIP
|
| 9:15–10:30 |
Keynote Panel
Partnering Landscape in China: Keeping Pace With Change
The China government is pouring billions of dollars into new drug development programs with the goal of having its own novel drugs reach the global market within the next few years. This has created a surge of new technology development, with thousands of novel molecules and targets being patented and developed in China. Plus, many of those companies previously focused solely on China's domestic market or traditional Chinese medicine (TCM) are now investing their large profits into the development of Western drugs. Thus, there is an increasingly rich environment for Western companies to partner with Chinese companies to bring their products to the Chinese market, or to identify novel technologies for development for the global market.
This panel of industry luminaries examines questions critical to any company wishing to successfully partner in China:
- What factors are driving China's rapid technology development?
- Are there novel technologies worth partnering with in China?
- How is partnering in China different than in the West?
- What factors are necessary to successfully partner in China?
- Is having a China entity helpful or even a requirement for success?
Moderator: Kewen Jin, PhD – General Manager, Charles River Greater China
Speakers:
- David Chen, MD, MBA – Executive VP and COO, 3SBio
- Edward Hu, MBA – COO, WuXi Apptec
- Xin Ma, PhD – Head of Global Drug Discovery, Innovation Center China, Bayer Schering Pharma
- Greg Wiederrecht, PhD, CLP – VP and Head, External Scientific Affairs, Worldwide Licensing, Merck Research Laboratories
|
| 10:30–11:00 |
Networking Break
|
10:30–17:00
One-to-one
meetings ►
|
| 11:00–12:00 |
Plenary Panel
China's Pharmaceutical Market: Unprecedented Growth
China has become the number three market for pharmaceuticals several years earlier than predicted. Annual growth rate is well over 22%, with some pharma companies growing their China business more than 50% per year and reaching over USD 1 billion in annual sales. There are many factors driving China pharmaceutical growth: healthcare reform, government policies and incentives, foreign investment, an aging population and the urbanization of China.
Topics to be explored by this panel include:
- How are these and other factors driving China's rapid growth?
- What role are government policies and incentive programs playing?
- Will this growth continue and what could impact it?
- Could backlash to the USA and the West slow market expansion for multinational corporations?
- When will China become the number two market for pharmaceuticals?
Moderator: Greg B. Scott – President and Founder, ChinaBio LLC
Speakers:
- Howard Sui, PhD, MBA – Managing Director, Merck Serono China
- Xiaobing Wu, PhD – Country Manager, Pfizer China
- Tony Zhang, PhD – Managing Director and Site Head, Eli Lilly Global RxD, China
- Ian Zhang, PhD, MBA – Head of Corporate Development, Asia Pacific, Life Technologies
- Larry Zhu, PhD, MBA – Director, External Scientific Affairs and Business Development, Janssen Pharmaceutical R&D, Asia Pacific
|
Company Presentations
[view list]
|
| 12:00–13:30 |
Lunch |
| 13:30–14:30 |
Panel
Financing Discovery and Development: Show Me the Money
To create and sustain the type of growth China's pharmaceutical market is experiencing requires huge investments from public and private sources. A robust value chain from discovery to commercialization must also be in place. This panel of investment and financial experts examines how China's dramatic growth has been funded, and if it can be sustained long term:
- How are government policies and incentive programs contibuting to growth?
- Is there a "valley of death" for early stage discovery in China as there is in the West?
- What role does private equity funding (VC/PE) play in China?
- How are the pharma companies and other foreign investments contributing to the growth?
Moderator: Ian Wisenberg – SVP, Strategic Development, ChinaBio LLC
Speakers:
- Alex Fowkes, JD – Executive Director, Head of R&D Business Development, Pfizer Global Research and Development
- Yuwen Liu, MBA – General Manager, BioBay
- Jonathan Wang, PhD, MBA – Senior Managing Director, OrbiMed Asia
- Yanning Yi, MBA – Executive Director, The Balloch Group
|
Company Presentations
[view list]
|
| 14:45–15:45 |
Workshop
Seven Model Structures for the Creation of Win-win Partnerships
The financial crisis in the developed economies has exacerbated a funding shortage for medium to long term investments in the life sciences sector, particularly for early stage novel therapies. As well as acquiring the rights to established or soon-to-be launched products, Chinese companies now have a range of options for the acquisition of technologies both for the local Chinese market and the global market.
Part I of this talk will explore seven models for the acquisition of rights that reflect the respective negotiating power of the Chinese partner and the Western rights holder through example models. All of these scenarios involve a win-win for both partners.
Part II of this talk will address the ten keys to help ensure long term success for any partnering arrangement.
Presenters:
- Brian Cunningham, JD – Senior Counsel and Co-chair of Life Science Group, Morrison & Foerster LLP
- Julian Thurston – Partner and Co-chair of Life Sciences Department, Morrison & Foerster LLP, UK
|
| 16:00–17:00 |
Workshop
How to Build and Protect Your IP Portfolio in China
This panel will discuss how to maximize IP value and avoid pitfalls in the context of building a patent portfolio for innovative pharma. It will also provide an overview of how IP protection can work for your company; how to build a valuable IP portfolio to attract investment and how to prevent the loss of IP assets. Use of Orange Book listing with USFDA and the Hatch-Waxman Act will also be discussed in the pharma IP context.
Presenters:
- Esther H. Lim, JD – Founding Managing Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Shanghai Office
- Ningling Wang, JD – Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Shanghai Office
|
| 17:00–18:00 |
Shuttle Buses to Banquet
|
| 18:00–20:00 |
Gala Banquet
 Pan Pacific Suzhou Hotel
259 Xin Shi Road
Suzhou, 215007, Jiangsu, China
[Visit website]
Suzhou is celebrated around the world for it’s elegant gardens. Boasting unique Chinese architectural grandeur and exquisite garden features, Pan Pacific Suzhou Hotel is the ideal venue for a networking reception. Balancing classical with contemporary design, the property fuses ancient Chinese aesthetics and traditional Suzhou gardens.
MORE
 Suzhou is China's well-known "city of gardens", which tops all others in both the number and the artistry of gardens. Dating from Pi Jiang Garden of the Eastern Jing Dynasty, Suzhou's art of gardening has undergone a history of 1,500 years. There were once over 200 gardens in the city, and 69 of them are still in good preservation today. The concept of Suzhou classical gardens has gone beyond the city limits, since it generally refers to all those private gardens built in the regions south of the Yangtze.
The Suzhou garden originated from the desire to retire from the strife of officialdom and to shun from worldly affairs. It seeks the return to nature and the cultivation of temperament. The ancient gardens of Suzhou were designed to be lived in as much as were the houses to which they were attached.
Suzhou gardens have their own characteristics in layout, structure and style. The Four Classical Gardens of Suzhou, i.e. The Surging Waves Pavilion, The Lion Grove Garden, The Humble Administrator's Garden and The Lingering Garden represent the different styles of Song, Yuan, Ming and Qing Dynasties.
 Pan Gate Scenic Area is known for its three landmarks. They include the Ruiguang Pagoda, the earliest pagoda in Suzhou built in 247 B.C., the Wu Gate Bridge, an over the water passage to the gate that serves as an entrance and was the highest bridge in Suzhou at the time, and Pan Gate. The Ruigang Pagoda is constructed of brick with wooden platforms and has simple Buddhist carvings at its base.
Pan Gate is part of the ancient city wall built in 514 B.C. that surrounded and protected Suzhou. Pan Gate was the only entrance to the wall that surrounded ancient Suzhou. It is also known throughout China for its architecture.
|
| 20:00–20:30 |
Shuttle Buses depart from evening event to Dushu Lake Hotel
|
| 8:30–9:00 |
Registration and Networking Breakfast
|
| 9:00–9:30 |
Networking Breakfast |
Company Presentations
[view list]
|
9:00–16:00
One-to-one
meetings ►
|
| 9:30–10:30 |
Panel
Major Issues in Licensing and Strategic Alliances Deals
China's drug market continues to grow rapidly and has already become an essential market for all big pharma and biotech companies. Overseas companies have different initiatives and plans to increase their market share in China, and Chinese companies also have different strategies and outlook towards domestic as well as international markets. Mutual collaborations exist in R&D, manufacturing, commercialization as well as after sale services. Our seasoned speakers in this panel will address in detail the key drivers in choosing a favorable collaboration model, the pros and cons in global licensing vs regional licensing and other major issues to be considered in licensing and strategic alliances deals.
Moderator: Ruediger Herrmann, PhD – Partner, WilmerHale
Speakers:
- Jie Liu D’Elia, PhD, MBA – VP, International Business Development, Simcere Pharma
- Michael Heerde, PhD – Director, Strategy and Business Development, Bayer HealthCare China
- Jonathan Wang, PhD – Senior Managing Director, OrbiMed Asia
- Richard Wang PhD, MBA – Director, Strategic Alliance and Collaboration, Asia, AstraZeneca
- Jimmy Wei, PhD – SVP, Business Development and Corporate Planning, Hutchison MediPharma
|
| 10:30–11:00 |
Networking Break
|
| 11:00–12:00 |
Panel
Leveraging IP Assets for M&A and Licensing Deals in China
Business development and deal making depend on secure intellectual property assets for predictable technology flow, capital generation, and partnerships. IP policies in China create opportunities and risks to be realized and managed as this enormous and expanding marketplace matures. For Western companies this is still a major stepping stone when considering partnerships with Chinese companies. In this session, representatives from big pharma will discuss their IP concerns in China. They will also give hands-on advice to Chinese companies on how to manage and secure IP rights to attract pharma, form strong partnerships, preserve value, and secure capital investment. Panelists will provide insights to existing and emerging IP issues for R&D, business development, capital investment, and government partnerships in China.
Moderator: Alfred W. Zaher, JD – Partner, Blank Rome LLP
Speakers:
- Martina Molsbergen – CEO, C14 Consulting Group, LLC
- Jianzhong (David) Shen, JD, PhD – Asia Regional IP Counsel, Eli Lilly
- Shawn Shiqing Li, JD, PhD – Blank Rome, LLP
- Breaux Walker – Managing Director, JMP Securities LLC
- Huacheng Wei, PhD – President, Beijing Pharmaceutical Group Co, Ltd
|
| 12:00–13:30 |
LUNCH
|
| 13:30–14:30 |
Executive Interview
The Road to China: The Tales of Two CEOs
There are many stories of success—and struggles—in China's life science industry. Two entrepreneurs who came to China with little more than their dreams, which they turned into successful companies, will be featured in this unique interview session. Dr Xiaochuan Wang moved her family back to Shanghai after 20 years in the USA to launch Sundia, now one of the leading China CROs focused on new drug discovery. John Oyler, a successful entrepreneur in the USA, co-founded and built BioDuro, a pre-clinical CRO in Beijing which was recently acquired by PPD. Eric Pierce, Publisher of BioCentury, will lead the interview.
Moderator: Eric Pierce – Publisher, BioCentury
Speakers:
- John Oyler – Former CEO, BioDuro
- Xiaochuan Wang, PhD – Chairman and CEO, Sundia MediTech Co., Ltd
|
Company Presentations
[view list]
|
| 14:30–15:30 |
Panel
Regulatory Environment: Trials and Tribulations
Moderator: Dajun Yang, PhD – CEO, Ascentage Pharma
Speakers:
- Avery Ince, MD, PhD – Medical Director, MSD China
- J. Robert (Bob) Powell, PhD – Scientific Advisor, Roche (China) Holding Ltd
- Maria Song, PhD, MD – President, VPS-CRO Group
- Dan Zhang, MD, MPH – Chairman and CEO, Fountain Medical Development Ltd
|
| 15:30–16:30 |
Closing Reception
Cold Spring Harbor Asia Conference Center, Exhibit Floor
299 Qiyue Road, Dushu Lake Higher Education Town,
Suzhou Industrial Park, Suzhou, Jiangsu 215123 China
[Visit website]
|
